HC Wainwright Has Negative Outlook of CMPX FY2025 Earnings

Key Points

• HC Wainwright has reduced its FY2025 earnings per share (EPS) estimate for Compass Therapeutics to ($0.55), down from a prior estimate of ($0.54), while maintaining a "Buy" rating with a price target of $24.00.
• Guggenheim and Raymond James have upgraded their price targets to $12.00 and $9.00, respectively, reflecting a generally positive outlook among analysts despite the lowered earnings estimate.
• The company's stock is currently trading at $3.04 with a market capitalization of approximately $419.69 million, showing volatility in price with a 12-month low of $1.15 and a high of $4.08.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Compass Therapeutics in a research note issued to investors on Monday, August 11th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.55) for the year, down from their prior estimate of ($0.54). HC Wainwright has a "Buy" rating and a $24.00 price objective on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics' FY2027 earnings at ($0.49) EPS.

Other equities analysts also recently issued research reports about the stock. Guggenheim lifted their price target on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday. Raymond James Financial upgraded shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a research report on Tuesday, July 1st. Finally, D. Boral Capital restated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $12.89.

Compass Therapeutics Price Performance

Shares of CMPX traded down $0.07 on Thursday, reaching $3.04. The company's stock had a trading volume of 137,034 shares, compared to its average volume of 1,410,221. The stock has a market capitalization of $419.69 million, a P/E ratio of -6.74 and a beta of 1.49. The stock's 50 day simple moving average is $2.78 and its two-hundred day simple moving average is $2.50. Compass Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01).

Institutional Trading of Compass Therapeutics

Several hedge funds have recently modified their holdings of the company. Invesco Ltd. lifted its position in shares of Compass Therapeutics by 11.3% during the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company's stock valued at $57,000 after buying an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Compass Therapeutics by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company's stock worth $463,000 after buying an additional 5,590 shares during the period. ProShare Advisors LLC increased its holdings in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after buying an additional 9,451 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Compass Therapeutics by 31.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after buying an additional 11,326 shares during the period. Finally, Creative Planning acquired a new position in Compass Therapeutics in the 2nd quarter worth approximately $30,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.